Clinuvel Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI
This Sustainability assessment for Clinuvel Pharmaceuticals Ltd represents its reporting of the United Nations Sustainable Development Goals. This Disclosure rating covers seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Life below Water'. The analysis of Clinuvel Pharmaceuticals Ltd incorporates information from across the internet as well as from available disclosures by Clinuvel Pharmaceuticals Ltd.
Clinuvel Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.5; made up of an environmental score of 8.0, social score of 6.4 and governance score of 8.0.
7.5
High ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1737978896147)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
149 | Torrent Pharmaceuticals Ltd | 7.6 | High |
149 | Virbac SA | 7.6 | High |
160 | Clinuvel Pharmaceuticals Ltd | 7.5 | High |
160 | C4X Discovery Holdings PLC | 7.5 | High |
160 | Ascentage Pharma Group International | 7.5 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1737978896147)
Frequently Asked Questions
Does Clinuvel Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Clinuvel Pharmaceuticals Ltd disclose current and historical energy intensity?
Does Clinuvel Pharmaceuticals Ltd report the average age of the workforce?
Does Clinuvel Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?
Does Clinuvel Pharmaceuticals Ltd disclose its ethnicity pay gap?
Does Clinuvel Pharmaceuticals Ltd disclose cybersecurity risks?
Does Clinuvel Pharmaceuticals Ltd offer flexible work?
Does Clinuvel Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Clinuvel Pharmaceuticals Ltd disclose the number of employees in R&D functions?
Does Clinuvel Pharmaceuticals Ltd conduct supply chain audits?
Does Clinuvel Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Clinuvel Pharmaceuticals Ltd conduct 360 degree staff reviews?
Does Clinuvel Pharmaceuticals Ltd disclose the individual responsible for D&I?
Does Clinuvel Pharmaceuticals Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Clinuvel Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?
Does Clinuvel Pharmaceuticals Ltd disclose water use targets?
Does Clinuvel Pharmaceuticals Ltd have careers partnerships with academic institutions?
Did Clinuvel Pharmaceuticals Ltd have a product recall in the last two years?
Does Clinuvel Pharmaceuticals Ltd disclose incidents of discrimination?
Does Clinuvel Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?
Has Clinuvel Pharmaceuticals Ltd issued a profit warning in the past 24 months?
Does Clinuvel Pharmaceuticals Ltd disclose parental leave metrics?
Does Clinuvel Pharmaceuticals Ltd disclose climate scenario or pathway analysis?
Does Clinuvel Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Clinuvel Pharmaceuticals Ltd disclose the pay ratio of women to men?
Does Clinuvel Pharmaceuticals Ltd support suppliers with sustainability related research and development?
Does Clinuvel Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Clinuvel Pharmaceuticals Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Clinuvel Pharmaceuticals Ltd involved in embryonic stem cell research?
Does Clinuvel Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?
Does Clinuvel Pharmaceuticals Ltd disclose its waste policy?
Does Clinuvel Pharmaceuticals Ltd report according to TCFD requirements?
Does Clinuvel Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Clinuvel Pharmaceuticals Ltd disclose energy use targets?
Does Clinuvel Pharmaceuticals Ltd disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Clinuvel Pharmaceuticals Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Clinuvel Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.